|
Jan 2
|
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
|
|
Jan 2
|
Should You Buy the Dip in Novo Nordisk Stock Right Now?
|
|
Jan 2
|
Tirzepatide outpacing Wegovy in the obesity space
|
|
Jan 2
|
Weight loss drugs are changing the game, Eli Lilly exec says — but many still can't get them
|
|
Jan 1
|
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
|
|
Jan 1
|
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
|
|
Jan 1
|
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.
|
|
Dec 31
|
Historical Trends Warrant a Closer Look at Novo Nordisk (NVO) Call Options
|
|
Dec 31
|
GLP-1 questions emerge for 2025
|
|
Dec 31
|
Novo Nordisk A/S (NVO): A Bull Case Theory
|
|
Dec 31
|
Lilly and Novo Went Head-to-Head Over Weight-Loss Drugs in 2024. There’s a Clear Winner.
|
|
Dec 30
|
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
|
|
Dec 30
|
Is Novo Nordisk A/S (NVO) the Best Pharma Dividend Stock to Buy In 2024?
|
|
Dec 30
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
|
|
Oct 3
|
Eli Lilly’s Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers.
|
|
Oct 3
|
Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
|
|
Oct 2
|
European Equities Close Mostly Higher in Wednesday Trading; Euro Area Unemployment Unchanged in August
|
|
Oct 2
|
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn’t a Problem.
|
|
Oct 2
|
Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
|
|
Oct 1
|
Novo Nordisk (NVO) Stock Moves -0.89%: What You Should Know
|